BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/23/2024 4:13:00 AM | Browse: 167 | Download: 426
 |
Received |
|
2023-11-01 20:40 |
|
Peer-Review Started |
|
2023-11-01 20:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-11-29 01:42 |
|
Revised |
|
2023-12-07 10:25 |
|
Second Decision |
|
2023-12-24 23:31 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-01-02 06:51 |
|
Articles in Press |
|
2024-01-02 06:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-13 12:56 |
|
Publish the Manuscript Online |
|
2024-01-23 04:13 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Uveal melanoma: Recent advances in immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Francesco Saverio Sorrentino, Francesco De Rosa, Patrick Di Terlizzi, Giacomo Toneatto, Andrea Gabai, Lucia Finocchio, Carlo Salati, Leopoldo Spadea and Marco Zeppieri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marco Zeppieri, BSc, MD, PhD, Doctor, Doctor, Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, Udine 33100, Italy. markzeppieri@hotmail.com |
| Key Words |
Uveal melanoma; Immunotherapy; Ocular oncology; Tumor; Metastatic disease; Genetic mutations |
| Core Tip |
Our minireview will cover the latest studies about immunotherapy for uveal melanoma (UM) metastatic disease. Driver genes and oncogenic mutations have been largely investigated. Up to half of affected patients develop metastases that are the leading single cause of death after diagnosis of UM. Precise systemic therapy addressing metastatic UM and significantly improving the surveillance is not available for each single case. However, identifying predictive factors, achieving international consensus on surveillance protocols, aiming to inactivate micrometastases, and standardizing outcomes would be crucial to be able to effectively cure metastatic UM. |
| Publish Date |
2024-01-23 04:13 |
| Citation |
Sorrentino FS, De Rosa F, Di Terlizzi P, Toneatto G, Gabai A, Finocchio L, Salati C, Spadea L, Zeppieri M. Uveal melanoma: Recent advances in immunotherapy. World J Clin Oncol 2024; 15(1): 23-31 |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i1/23.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i1.23 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
